Get the Stockscreener App
0.43
5.43%
-0.0247
After Hours:
.46
0.03
+6.98%
Rallybio Corp stock is traded at $0.43, with a volume of 762.15K.
It is down -5.43% in the last 24 hours and up +31.86% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.4547
Open:
$0.4548
24h Volume:
762.15K
Relative Volume:
0.29
Market Cap:
$17.89M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.2348
EPS:
-1.8316
Net Cash Flow:
$-60.27M
1W Performance:
+5.86%
1M Performance:
+31.86%
6M Performance:
-50.87%
1Y Performance:
-66.92%
1-Day Range:
$0.43
$0.4661
1-Week Range:
$0.386
$0.495
52-Week Range:
$0.2201
$1.54
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.43 | 16.90M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio Corporation Stock Analysis and ForecastMarket-beating performance - Jammu Links News
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Why Rallybio Corporation stock attracts strong analyst attentionFree Access to Investment Community - Newser
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - TradingView
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest
Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz
RallyBio - Hartford Business Journal
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks
Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech
Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha
Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com
Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks
Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com
ImmunoPrecise Strengthens Board with 30-Year Biotech Veteran Jon Lieber from Rallybio - Stock Titan
Rallybio Finalizes Employment Agreement with CMO - TipRanks
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization - TipRanks
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk - TipRanks
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study - TradingView
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 By Investing.com - Investing.com South Africa
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - BioSpace
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 - Investing.com India
Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study - MarketScreener
Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders - Stock Titan
RLYBRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - mx.advfn.com
Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - Trumbull Times
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook By Investing.com - Investing.com Canada
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook - Investing.com
Rallybio shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Rallybio shareholders elect directors, ratify auditor - Investing.com
Rallybio Elects New Directors at Shareholder Meeting - TipRanks
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):